Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Sclerosis: early-phase trial registry
12 of 27 indexed Systemic Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 12 currently recruiting · #598 of 28,707 conditions by registered trial count
Systemic Sclerosis: 27 US clinical trials tracked, 12 recruiting.
Systemic Sclerosis is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 2 of these trials.
Enrollment posture brief
Registry condition systemic-sclerosis
OPEN 12 | RECR 44% | LATE 3 | EARLY 17 | RANK #598 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Undifferentiated Leukemia (44% recruiting · 9 trials)
Systemic Sclerosis lists 12 open slots (44% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Systemic Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Systemic Sclerosis is recruiting above its size-band peers.
12 of 27 indexed trials (44.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Systemic Sclerosis trials is spread across many organizations.
Sanofi accounts for 2 of 27 trials (7.4%). 23 distinct sponsors appear on at least one study for this condition label.
-
Most Systemic Sclerosis trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 27 trials that report a genuine target (sentinel values excluded). 20 of those (74.1%) plan for fewer than 100 participants.
-
Systemic Sclerosis research is mostly interventional.
23 interventional and 4 observational studies make up this index (85.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
New Orleans Pulmonary Hypertension Biobank
Louisiana State University Health Sciences Center in New Orleans
NCT03269630
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT05869955
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nkarta
NCT06733935
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
NCT06925542
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
The University of Texas Health Science Center, Houston
NCT05989763
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Allogene Therapeutics
NCT07085104
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
M.D. Anderson Cancer Center
NCT06434363
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Hospital for Special Surgery, New York
NCT03844061
A Study of AZD0120 in Autoimmune Diseases
AstraZeneca
NCT07295847
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
Stephan Grupp MD PhD
NCT05029336
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Cabaletta Bio
NCT06328777
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Paul Szabolcs
NCT03630211
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
AstraZeneca
NCT05925803
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
Brigham and Women's Hospital
NCT05715463
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Synthekine
NCT06544330
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Kyverna Therapeutics
NCT06400303
Scleroderma Registry
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00074568
Oral Health and People With Systemic Sclerosis
University of Alabama at Birmingham
NCT01817361
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Sanofi
NCT02921971
Psychological Treatments for Scleroderma
Johns Hopkins University
NCT00007267
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Genentech
NCT01933334
Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis
University of Michigan
NCT03482219
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Sanofi
NCT01651143
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Johns Hopkins University
NCT01042158
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Hospital for Special Surgery, New York
NCT01670565
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
University of California, Los Angeles
NCT01051960
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
Northwestern University
NCT03438032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Systemic Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Systemic Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Systemic Sclerosis page
27 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Systemic Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Systemic Sclerosis trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Sclerosis condition card totals 27 registered trials; most-linked intervention Cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.